Biopharmaceutical profiling of sesamol: Physiochemical characterization, gastrointestinal permeability and pharmacokinetic evaluation

RSC Advances

Volumn 5, Issue 6, 2015, Pages 4083-4091

  Geetha, T ^a   Singh, Neha ^b   Deol, Parneet Kaur ^a   Kaur, Indu Pal ^a  

^a PANJAB UNIVERSITY   (India)

^b PANJAB UNIVERSITY   (India)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIOXIDANTS; BIOCHEMISTRY; MOLECULES; RATS; SOLUBILITY; TISSUE;

ANTIOXIDANT POTENTIAL; CLINICAL APPLICATION; DISTRIBUTION COEFFICIENT; ORAL BIOAVAILABILITIES; PHARMACOKINETIC EVALUATION; PHYSICOCHEMICAL PROPERTY; PHYSIOCHEMICAL CHARACTERIZATION; TISSUE DISTRIBUTIONS;

PHARMACOKINETICS;

EID: 84919667255     PISSN: None     EISSN: 20462069     Source Type: Journal    
DOI: 10.1039/c4ra10926k     Document Type: Article

References (38)

1. P. Budowski, Sesame oil, III antioxidant properties of sesamol, J. Am. Oil Chem. Soc., 1950, 27, 2647-2649.
2. K. P. Suja, A. Jayalekshmy and C. Arumughan, Free radical scavenging behavior of antioxidant compounds of sesame (Sesamum indicum L.) in DPPH system, J. Agric. Food Chem., 2004, 52, 912-915.
3. T. Kato, T. Harashima, N. Moriya, K. Kikugawa and K. Hiramoto, Formation of the mutagenic/carcinogenic imidazoquinoxaline-type heterocyclic amines through the unstable free radical Maillard intermediates and its inhibition by phenolic antioxidants, Carcinogenesis , 1996, 17, 2469-2476.
4. H. Y. Aboul-Enein, I. Kruk, A. Kladna, K. Lichszteld and T. Michalska, Scavenging effects of phenolic compounds on reactive oxygen species, Biopolymers, 2007, 86, 222-230.
5. R. Joshi, M. S. Kumar, K. Satyamoorthy, M. K. Unnikrisnan and T. Mukherjee, Free radical reactions and antioxidant activities of sesamol: pulse radiolytic and biochemical studies, J. Agric. Food Chem., 2005, 53, 2696-2703.
6. K. Hiramoto, N. Ojima, K. Sako and K. Kikugawa, Effect of plant phenolics on the formation of the spin-adduct of hydroxyl radical and the DNA strand breaking by hydroxyl radical, Biol. Pharm. Bull., 1996, 19, 558-563.
7. T. Geetha, R. Bhandari and I. P. Kaur, Sesamol: An efficient antioxidant with potential therapeutic benefits, J. Med. Chem., 2009, 5, 367-371.
8. R. Narasimhan, M. Vaithiyanathan and V. Janardanam, Neuroprotective effect of sesamol in glioma induced in rats, Biomed. Int., 2011, 2, 22-27.
9. V. Kakkar, A. K. Mishra, K. Chuttani, K. Chopra and I. P. Kaur, Delivery of sesamol loaded solid lipid nanoparticles to brain for menopause related emotional and cognitive central nervous system derangements, Rejuvenation Res., 2011, 14, 597-604.
10. I. P. Kaur and A. Saini, Sesamol exhibits antimutagenic activity against oxygen species mediated mutagenicity, Mutat. Res., 2000, 470, 71-76.
11. Z. Ying, N. Kherada, T. Kampfrath, G. Mihai, O. Simonetti, R. Desikan, K. Selvendiran, Q. Sun, O. Ziouzenkova, S. Parthasarathy and S. Rajagopalan, A modified sesamol derivative inhibits progression of atherosclerosis, Arterioscler., Thromb., Vasc. Biol., 2011, 31, 536-542.
12. S. Jnaneshwari, M. Hemshekhar, R. M. Thushara, M. S. Shanmuga, M. S. Santhosh, K. Sunitha, R. L. Shankar and K. Kemparaju, Sesamol ameliorates cyclophosphamide-induced hepatotoxicity by modulating oxidative stress and inflammatory mediators, Anti-Cancer Agents Med. Chem., 2014, 14(10), 975-983.
13. A. Gupta, S. Sharma, I. Kaur and K. Chopra, Renoprotective effects of sesamol in ferric nitrilotriacetate-induced oxidative renal injury in rats, Basic Clin. Pharmacol. Toxicol., 2009, 104, 316-321.
14. K. Mishra, P. S. Srivastava and N. K. Chaudhury, Sesamol as a potential radioprotective agent: in vitro studies, Radiat. Res., 2011, 176 , 613-623.
15. S. Ramachandran, R. N. Prasad and S. Karthikeyan, Sesamol inhibits UVB-induced ROS generation and subsequent oxidative damage in cultured human skin dermal fibroblasts, Arch. Dermatol. Res., 2010, 302, 733-744.
16. S. Sharma and I. P. Kaur, Development and evaluation of sesamol as an antiaging agent, Int. J. Dermatol., 2006, 45, 200-208.
17. P. Y. Chu, D. Z. Hsu, P. Y. Hsu and M. Y. Liu, Sesamol downregulates the lipopolysaccharide-induced inflammatory response by inhibiting nuclear factor-kappa B activation, Innate Immun., 2010, 16, 333-339.
18. D. Z. Hsu, P. Y. Chu and M. Y. Liu, The non-peptide chemical 3,4-methylenedioxyphenol blocked lipopolysaccharide (LPS) from binding to LPS-binding protein and inhibited proin flammatory cytokines, Innate Immun., 2009, 15, 380-385.
19. G. Fiese and J. H. Perrin, A note on the absorption of 3-methoxy-N-methyl-morphinan hydrochloride from the rat stomach, J. Pharmacokinet. Pharmacodyn., 1968, 20 , 98-101.
20. R. R. Levine and E. W. Perikan, Influence of experimental procedures and dose on the intestinal absorption of an onium compound, benzomethamine, J. Pharmacol. Exp. Ther., 1961, 131, 319-327.
21. K. C. Jan, C. T. Ho and L. S. Hwang, Elimination and metabolism of sesamol, a bioactive compound in sesame oil, in rats, Mol. Nutr. Food Res. , 2009, 53, 36-43.
22. K. C. Jan, C. T. Ho and L. S. Hwang, Bioavailability and tissue distribution of sesamol in rat, J. Agric. Food Chem., 2008, 56, 7032-7037.
23. S. Tamano, M. Hirose, H. Tanaka, E. Asakawa, K. Ogawa and N. Ito, Forestomach neoplasm induction in F344/DuCrj rats and B6C3F1 mice exposed to sesamol, Jpn. J. Cancer Res., 1992, 83, 1279-1285.
24. M. Hirose, S. Fukushima, T. Shirai, R. Hasegawa, T. Kato, H. Tanaka, E. Asakawa and N. Ito, Stomach carcinogenicity of caffeic acid, sesamol and catechol in rats and mice, Jpn. J. Cancer Res., 1990, 81, 207-212.
25. E. A. Nera, F. Iverson, E. Lok, C. L. Armstrong, K. Karpinski and D. B. Clayson, A carcinogenesis reversibility study of the effects of butylated hydroxyanisole on the forestomach and urinary bladder in male Fischer 344 rats, Toxicology, 1988, 53, 251-268.
26. M. Kagawa, K. Hakoi, A. Yamamoto, M. Futakuchi and M. Hirose, Comparison of reversibility of rat forestomach lesions induced by genotoxic and non-genotoxic carcinogens, Jpn. J. Cancer Res., 1993, 84, 1120-1129.
27. M. Kaneko, K. Morimura, T. Nishikawa, H. Wanibuchi, N. Takada, H. Osugi, H. Kinoshita and S. Fukushima, Different genetic alterations in rat forestomach tumors induced by genotoxic and nongenotoxic carcinogens, Carcinogenesis , 2002, 23, 1729-1735.
28. T. Masui, M. Asamoto, M. Hisose, S. Fukushima and N. Ito, Regression of simple hyperplasia and papillomas and persistence of basal cell hyperplasia in the forestomach of F344 rats treated with butylated hydroxyanisole, Cancer Res., 1987, 47, 5171-5174.
29. H. A. Krebs and J. C. Speakman, Dissociation constant, solubility and the pH value of the solvent, J. Chem. Soc., 1945, 593-595.
30. D. Fleisher, C. Li, Y. Zhou, L. H. Pao and A. Karim, Drug, meal and formulation interactions influencing drug absorption after oral administration-clinical implications, Clin. Pharmacokinet., 1999, 36, 233-254.
31. T. Koizumi, T. Arita and K. Kakemi, Absorption and excretion of drugs. XIX Some pharmacokinetic aspects of absorption and excretion of sulphonamides. (1) Absorption from rat stomach, Chem. Pharm. Bull., 1964, 12(4), 413-420.
32. A. Malkia, L. Murtomaki, A. Urtti and K. Kontturi, Drug permeation in biomembranes: in vitro and in silico prediction and influence of physicochemical properties, Eur. J. Pharm. Sci., 2004, 23, 13-47.
33. L. K. Wadhawa and P. D. Sharma, Glycol amide esters of 6- methoxy-2-naphthyl acetic acid as potential prodrugs-physicochemical properties, chemical stability and enzymatic hydrolysis, Int. J. Pharm., 1995, 118, 31-39.
34. K. Wakita, M. Yoshimoto, S. Miyamoto and H. Watanabe, A method for calculation of the aqueous solubility of organic compounds by using new fragment solubility constants, Chem. Pharm. Bull., 1986, 34 , 4663-4681.
35. FDA, U., US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research. Guidance for industry: E10 choice of control group and related issues in clinical trials. http://www.fda.gov/cder/guidance/4155fnl.htm. 2000.
36. USFDA, Guidance for Industry: estimating the maximum safe starting dose in initial clinical trials for therapeutics in adult healthy volunteers, http://www.fda.gov/downloads/Drugs/Guidances/UCM078932.pdf, Accessed on 12 November 2014, 2005.
37. A. Leo, C. Hanch and D. Elkins, Partition coefficients and their uses, Chem. Rev. , 1971, 71, 6.
38. ICH, Guideline for industry pharmacokinetics: Guidance for repeated dose tissue distribution studies, 1995.